24. July 2019

ESOP – Constitution

  1. Name
    The name of the Society shall be the European Society of Oncology Pharmacy, hereby known as ESOP.
  2. Financial Year
    The financial year shall be the calendar year.
  3. Aim
    The aim of ESOP is to support optimal treatment for cancer patients.
  4. Objectives
    4.1. to develop and promote clinical and oncology pharmacy practice through:
    – education and training
    – safe handling and administration of drugs
    – quality management
    – research and development
    – pharmaceutical care
    4.2. To make information on knowledge and achievements in cancer treatment and activities available to the public.
    4.3. To spread the information by publications, professional activities as well as educational lectures an seminars.
    4.4. To promote communication and knowledge exchange between hospital, community and other professionals in the field of oncology pharmacy.
  5. Membership
    5.1. Membership can be granted to European oncology pharmacy practitioners and others willing to pursue the aim and the objectives of ESOP.
    5.2. The ESOP as federation is based on national groups or associations for oncology pharmacy in Europe and any other country worldwide.
    5.3. The national groups or associations shall pay a fee for each of their members. The fee to be paid shall be decided upon by the delegate assembly
    5.4. For countries without a formal national based association which officially is recognised to represent Oncology Pharmacy, the ESOP Delegate Assembly (DA) will name and adopt delegates as liaison officers for the upcoming 3 years.
    5.5. Individual membership is possible for those who are willing to pursue the aim and the objectives of ESOP, after approval on a case-by-case basis by the Board. Individual members shall pay a fee.
  6. The delegate assembly
    6.1. The delegate assembly is the highest organ of ESOP, open for all delegates, liaisons and individual members.
    6.2. The delegate assembly shall be held at least every three years, with the Board deciding the exact date.
    6.3. Notice in writing of the date together with an agenda of the delegate assembly shall be sent to all delegates not less than thirty days prior to the date fixed for the meeting.
    6.4. Every EU country and every non-EU country has the right to announce a delegate as a representative member of the delegate assembly.
    6.5. Liaison delegates and individual members from EU countries and from non-EU countries have the same rights and duties as all other delegates. They can become elected as officers of ESOP; an active voting will only be recognised but not counted.
    6.6 .The members of the delegate assembly shall make decisions under legal EU condition by majority rule on the base of one country one vote.
    6.7. Election of the Board shall be held at the delegate assembly, at least every 3 years
  7. The Board
    7.1. The Board shall consist of a minimum of three persons, as follows:
    (i)     President
    (ii)    Vice-President
    (iii)   Secretary
    7.2. Decisions of the Board shall be made unanimously.
    7.3. The Board shall be responsible for the management of the Society and shall carry out all decisions made by the delegate assembly
  8. Change of constitution
    The constitution of ESOP may be changed by a three-quarters majority of those present at a delegate assembly.
  9. Dissolution
    The ESOP may be dissolved by a three-quarter majority of all delegates.
  10. Liquidation
    The members of the Board shall carry out the liquidation.

Hamburg, 01/27/2006

Robert Terkola
Isabelle Glorieux
Irena Netiková
Czech Republic
Vesna Pavlica
S. Theophanous-Kitiri
Eva Honore
Klaus Meier
Ioanna Saratsiotou
Franca Goffredo
Camille Groos
Agnes Jarmolovicz
Jerzy Lazwoski
Monica Sonc
Monique Ackermann
Per Hartwig

About us

The European Society of Oncology Pharmacy (ESOP), founded in 2000 in Prague, is the largest organization of oncology pharmacists in the world with a membership of approx. 3.500 members from 62 countries. Each country has one vote in the delegate assembly. The ESOP is full member of the European Cancer Organisation.

Aim and Objective

The aim of ESOP is to support optimal treatment for cancer patients. In order to achieve this aim, ESOP offers a high-quality further education, guidelines and ongoing development of practices in all parts of oncology pharmacy.


European Society of Oncology Pharmacy (ESOP)
c/o DGOP e.V.
Veritaskai 6
21079 Hamburg

E-Mail: membershipservice[at]
Phone.: +49  40 466 500 300
Fax: +49 40 466 500 100


19. May 2019

ESOP – the world’s largest multinational oncology pharmacy society,
supporting the interests of cancer patients.


Dear members and friends,

When we were founded in Prague in May 2000, we hoped to contribute to a great global
development of cooperation in oncology pharmacy.

Unfortunately, the small majority in the ISOPP, which was then made up by a few countries,
voted against allowing regional issues to flow more into society. The course
was set to regard only specialists as actors and all others as additional
members without influence. This hurt me a lot, especially as the outgoing first
elected President, because our motto at the beginning was: “Unity in diversity”.

This also meant that the ISOPP was more oriented towards the interests of financially
strong sponsors and their issues, whereas the ESOP wanted to give members in
the EU as well as around the world the opportunity to find common answers for
daily practice issues. For this purpose, the “Quality Standard for Oncology
Pharmacy Service” (QuapoS) introduced by the DGOP was then developed jointly by
all members from all countries at regular intervals and is now used in many
countries around the world as a guideline for answering questions about dealing
with oncology drug issues.

As early as 2005, the number of members grew so strongly that it was decided to allow
national associations that deal with oncology pharmacy to register their
members as members of the ESOP, with the stipulation that common goals of the
ESOP can be implemented regionally better and more sustainably .

This means that countries that are too small or that are unable to found their own oncology
pharmacy society for other reasons still have the option of naming a regional
contact person.

The activities in oncology pharmacy, which initially extended to therapy in
clinics, have continued to develop. This is not only reflected in the position
paper “High Standards of Oncology Pharmacy”, but also
in the orientation of the QuapoS from manufacturing to patient-related

ESOP members support cancer patients in community pharmacies, outpatient departments and
clinics. Colleagues in licensing authorities, supervisory offices and
administrations are confronted with questions that deal with treatment but
above all with prevention and pharmaceutical care. They all found a home in

In 62 countries around the world, colleagues are proud to contribute to better
support for cancer patients as ESOP members and thus to make everyone aware of
the role of our profession.

Data protection plays a major role for us. Members are continuously addressed
through newsletters or letters for as long as they want. Information about
individuals is never passed on to external interests or sponsors. We protect
you from unauthorized access as far as we can and continue to count on your
unconditional support.


Klaus Meier

ESOP President

Please click on the picture to participate in the questionnaire

Dear Colleagues,

2020 was different than we could have imagined or expected 12 months ago.
As a consequence, the healthcare systems and the entire establishment across the world had been subject to extensive scrutiny on their sustainability.
COVID-19 spread and moved unstoppable across the world. Those countries with cases early in the year had to defend themselves without precise knowledge. Saving people was the only principle that applied. Scenarios of foreclosure, of the relentless struggle of the people in the health sector, were enthusiastically praised by the people all over the world and the title of “key professionals” became the norm. 
In parallel, with facts coming to light, fears of prehistoric times events became real. Protective suits and masks became rare, ventilators were too few, and drugs, in particular for anesthesia, became scarce. During the previous 3 months we asked fellow key professionals about their perception of the situation and provided weekly reports on this. These results are available to everyone on our homepage
We are still intrigued by the insidiousness of the disease and still see no magic cure on the horizon. 
Driven not only by concern but also by economic interests, vaccines are brought to market in a rush and medicinal products are used in individual periods for symptomatic treatment on or off-label.

How will it go on? Will we get on top of it? What consequences will this have on life as we know it and what measures we will have to deal with? 
For this and in order to gain more knowledge for the short term and for the future, our team has worked together with the EAHP to create a structured approach to collect this perceptions and facts at wider scale and continue to provide monthly updates.
For this, we will need your support in taking a few minutes each month to fill in this questionnaire. It is anonymous and in order to be able to carry out a correct evaluation, we ask you this time for two things:

  1. Please take part in it continuously over the next 6 months so that we can collect more precise statistical data and
  2. Please use the same account / password each time so that an evolution over time is available for you to read.

So far we have received a feedback from fellow professionals from 63 countries. We’ve come a long way some might say, but our work is not complete.
With wider audience and feedback from a larger number of professionals we will have an improved insight on the reality as it is seen by those who, as health professionals, do not cease to let the appearance of the profession be recognised as a calling.

Klaus Meier, President

This team of colleagues from all over the world will accompany the questionnaire campaign over the next 6 months.
We would be delighted if as many people as possible could participate on a permanent basis.
You will have time to answer the questionnaire one week after its publication.  Even if you cannot answer everything, it is important to participate.
The questionnaire is available in German, English, French, Spanish, Russian, Italian and Bosnian.
We look forward to your participation.